Device Center Says “522” Actions Are Up, But Industry Has No Cause To Worry

FDA's device center is increasingly emphasizing its ability to compel companies to collect specified postmarket surveillance data for marketed devices, according to Susan Gardner, director of the agency's Office of Surveillance & Biometrics